Galera Therapeutics, Inc.
GRTX
$0.09
$0.00-4.61%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -12.30% | -13.51% | -62.02% | -62.18% | -39.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.69% | -7.09% | -61.65% | -73.03% | -57.11% |
| Operating Income | 15.69% | 7.09% | 61.65% | 73.03% | 57.11% |
| Income Before Tax | -0.88% | 3,204.93% | 76.00% | 73.55% | 63.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.88% | 3,204.93% | 75.13% | 73.55% | 63.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.88% | 3,204.93% | 75.13% | 73.55% | 63.66% |
| EBIT | 15.69% | 7.09% | 61.65% | 73.03% | 57.11% |
| EBITDA | -- | 7.39% | 61.73% | 73.11% | 57.14% |
| EPS Basic | -1.37% | 907.18% | 86.26% | 85.41% | 90.93% |
| Normalized Basic EPS | -0.99% | 25.20% | 78.85% | 85.44% | 79.92% |
| EPS Diluted | -1.37% | 907.18% | 86.26% | 85.41% | 90.93% |
| Normalized Diluted EPS | -0.99% | 25.20% | 78.85% | 85.44% | 79.92% |
| Average Basic Shares Outstanding | 0.00% | 77.94% | 81.10% | 81.10% | 81.10% |
| Average Diluted Shares Outstanding | 0.00% | 77.94% | 81.10% | 81.10% | 81.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |